Altre lingue Axsome Therapeutics, Inc.

Azioni

AXSM

US05464T1043

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
74,89 ^USD	+1,53%		+2,48%	-5,91%

29/04	Il trial di fase 3 di Axsome Therapeutics per il trattamento dell'Alzheimer è ad alto rischio e alto guadagno, dice Morgan Stanley	MT
29/04	AXSOME THERAPEUTICS, INC. : cambio di rotta da parte di Morgan Stanley	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Axsome Therapeutics Recognizes May as Mental Health Awareness Month	13:01
North American Morning Briefing : More Earnings -2-	30/04
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says	29/04
Axsome Therapeutics highlights innovative neuroscience portfolio at the american academy of neurology 2024 annual meeting	16/04
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	15/04
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	15/04
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6	10/04
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	02/04
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	01/04
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	01/04
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	25/03
Axsome Therapeutics : AXS-12 SYMPHONY Results - Slides	25/03
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	25/03
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	25/03
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	25/03
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy	25/03
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	25/03
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	19/03
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	19/03
Axsome Therapeutics Insider Sold Shares Worth $2,257,449, According to a Recent SEC Filing	18/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Axsome Therapeutics, Inc.

Azioni

AXSM

US05464T1043

Altre lingue

Filtri